Internal Medicine, Nephrology · New Orleans, LA
NPI
1679571921
Since 2005
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
3434 Prytania St, Ste 300
New Orleans, LA, 70115
Phone (504) 897-4425
Groups this clinician bills Medicare through
Medicare paid, 2024
$82K
771 services
Medicare patients, 2024
226
Average age 74
Drug cost, 2024
$1.1M
2,677 prescriptions
Company payments, 2025
$744
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by April J Fox was code 99214 (office e&m - established), 238 times for 102 patients. In total April J Fox billed 771 services in 26 codes, and Medicare paid $82K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 238 | 102 | $88.51 | $21K |
| 99233 Hospital E&M - Subsequent | Facility | 163 | 70 | $95.28 | $16K |
| 99223 Hospital E&M - Initial | Facility | 51 | 51 | $139.52 | $7,116 |
| G0420 Face-to-face educational services related to the care of chronic kidney disease; individual, per session, per one hour | Office | 51 | 15 | $79.69 | $4,064 |
| 90937 Hemodialysis | Facility | 46 | 23 | $82.20 | $3,781 |
| 99291 Critical Care E&M | Facility | 35 | 18 | $172.17 | $6,026 |
| 99215 Office E&M - Established | Office | 34 | 27 | $133.55 | $4,541 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 22 | 22 | $130.90 | $2,880 |
| 99232 Hospital E&M - Subsequent | Facility | 17 | 16 | $63.81 | $1,085 |
| 99497 Care Management/Coordination | Office | 13 | 13 | $62.31 | $810 |
| 99213 Office E&M - Established | Office | 11 | 11 | $66.35 | $730 |
By year: 2022 $86K for 774 services; 2023 $84K for 913 services; 2024 $82K for 771 services.
Medicare prescription drug claims, 2024
In 2024, the drug April J Fox prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 203 prescriptions and refills. In total April J Fox wrote 2,677 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 203 | 279 | 44 | $154K |
| Furosemide Generic | 161 | 319 | 45 | $642 |
| Losartan Potassium Generic | 145 | 382 | 45 | $872 |
| Allopurinol Generic | 119 | 318 | 38 | $647 |
| Atorvastatin Calcium Generic | 117 | 303 | 31 | $761 |
| Carvedilol Generic | 113 | 263 | 35 | $754 |
| Nifedipine Er Nifedipine | 100 | 238 | 32 | $2,087 |
| Jardiance Empagliflozin | 100 | 126 | 28 | $74K |
| Amlodipine Besylate Generic | 52 | 142 | 22 | $251 |
| Ozempic Semaglutide | 50 | 74 | Under 11 | $70K |
| Rosuvastatin Calcium Generic | 48 | 136 | 18 | $1,008 |
| Alendronate Sodium Generic | 47 | 103 | 11 | $306 |
| Prolia Denosumab | 45 | 270 | 27 | $79K |
| Metoprolol Succinate Generic | 44 | 100 | 13 | $702 |
| Valsartan Generic | 41 | 106 | 11 | $1,260 |
Brand drugs: - claims; generic drugs: 1,877 claims; opioid claims: 14.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid April J Fox $744 ($744 in general payments such as food, travel and fees) from 14 companies. The largest payer was Calliditas Therapeutics US Inc. with $150.
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 9 | $150 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $103 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 5 | $95.68 |
| Amgen Inc. AMGN | 4 | $83.72 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $81.34 |
| Fresenius USA Marketing, Inc. | 2 | $47.95 |
| Novo Nordisk Inc NVO | 2 | $41.84 |
| Vifor Pharma, Inc. | 1 | $26.92 |
| Xeris Pharmaceuticals, Inc. | 1 | $25.98 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $22.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.